Biomarkers in Non-Small Cell Lung Cancer: Opportunity and Challenge
Kristen Kreamer, CRNP, Beth Eaby-Sandy, CRNP, Victoria Sherry, CRNP,
and Susan Stonehouse-Lee, CRNP
From Fox Chase Cancer Center, Philadelphia, and Abramson Cancer Center, University of Pennsylvania Health Systems, Philadelphia, Pennsylvania
Kristen Kreamer has served on advisory boards for Genentech; Beth Eaby-Sandy has served on speakers' bureaus for Genentech, Eli Lilly & Co., Merck & Co., and has acted as a consultant for Amgen.
Correspondence to: Kristen Kreamer, CRNP, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.
J Adv Pract Oncol 2011;2:163–175 |
DOI: 10.6004/jadpro.2011.2.3.3 |
© 2011 Harborside Press®
Lung cancer, a major global public health issue, is the leading cause of cancer death in the United States. In spite of the importance of this disease, there has been only a 3% improvement in 5-year survival over the past 30 years. While there have been some recent promising developments in screening and diagnosis, there is an urgent need to improve on therapy so that more people can be cured or have a longer life. In the field of biomarkers for non–small cell lung cancer we are beginning to characterize lung tumors by their molecular signature and design therapy accordingly. This article will address biomarkers for non–small cell lung cancer, with an emphasis on those that are either already used in clinical practice or being studied in current clinical trials. Epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS), excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase 1 (RRM1), and echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase (ELM4-ALK) will be discussed. For each marker, we will address normal function in the cancer cell; impact on function when it is present, absent, or mutated; testing for the marker; incidence or frequency of the marker as well as characteristics (if known) of patients more likely to be positive for the marker; and function of the marker as prognostic, predictive, or both. We will also address implications for the advanced practitioner.
For access to the full length article, please sign in